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Abstract
Traumatic brain injury (TBI) research commonly measures long-term functional outcome, but studies often suffer from
missing data as patients are lost to follow-up. This review assesses the extent and handling of missing outcome data in the
TBI literature and provides a practical guide for future research. Relevant electronic databases were searched from January
1, 2012 to October 27, 2017 for TBI studies that used the Glasgow Outcome Scale or Glasgow Outcome Scale-Extended
(GOS/GOSE) as an outcome measure. Studies were screened and data extracted in line with Cochrane guidance.
A total of 195 studies, 21 interventional, 174 observational, with 104,688 patients were included. Using the reported follow-up
rates in a mixed model, on average 91% of patients were predicted to return to follow-up at 6 months post-injury, 84% at 1 year,
and 69% at 2 years. However, 36% of studies provided insufficient information to determine the number of subjects at each time-
point. Of 139 studies that did report missing outcome data, only 50% attempted to identify why data were missing, with just 4
reporting their assumption on the ‘‘missingness mechanism.’’ The handling of missing data was heterogeneous, with the most
common method being its exclusion from analysis. These results confirm substantial variability in the standard of reporting and
handling of missing outcome data in TBI research. We conclude that practical guidance is needed to facilitate meaningful and
accurate study interpretation, and therefore propose a framework for the handling of missing outcome data in future TBI research.
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Introduction
Traumatic brain injury (TBI) studies commonly suffer frompatient attrition resulting in missing outcome data.1–3 In-
adequate handling of missing data can decrease power, violate
intention-to-treat analyses, and introduce bias. Missing data first
gained attention in the 1970s when Rubin introduced the concept
of the ‘‘missingness mechanism’’ or the reason why data are
missing.4 The missingness mechanism describes data as ‘‘missing
completely at random’’ (MCAR), ‘‘missing at random’’ (MAR),
or ‘‘missing not at random’’ (MNAR). Importantly, the mecha-
nism is not only relevant to the interpretation of conclusions, but
also informs what statistical approaches may best be used for
handling missing data.
In MCAR, patients missing due to loss to follow-up do not differ
in any respect from those remaining, leaving conclusions unaf-
fected. However, in most clinical research, MCAR rarely applies
with previous studies in TBI research assuming missing data to be
MAR.1–3 MAR occurs when loss to follow-up is random, condi-
tional on observed and measurable patient characteristics and can
therefore be statistically corrected for. In MNAR however, the
outcome itself (or unobserved characteristics related to missing-
ness) determines likelihood of follow-up. Its identification requires
knowledge of the population, disease, and follow-up process as no
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statistical test alone is able to identify data as MNAR. Importantly,
given that this is unmeasurable, the bias introduced by MNAR
cannot be overcome by statistical correction alone and requires
additional techniques. Therefore, researchers should apply caution in
drawing conclusions when lost patients differ from those remaining
in the study due to the potential of missing data being MNAR.
The hazard of missing data to accurate study interpretation has
been recognized by multiple regulatory bodies including the Eu-
ropean Medicine Agency (EMA), National Research Council, and
Food and Drug Administration.5–7 The EMA provides specific
recommendations for handling missing values in clinical trials,
where unbalanced attrition between treatment arms can introduce
bias. Recommendations include study design features to minimize
the amount of missing data, anticipation of missing data with
predefined plans for analyses, and exploration of the missingness
mechanism with post hoc sensitivity analyses. Although similar
principles can be applied to observational studies, specific guide-
lines relating to handling of missing data in observational studies
are lacking. Given the predominance of observational studies in
TBI research including emerging, large volume data series, guid-
ance is urgently required.
The aims of this review are therefore two-fold. First, to assess the
quantity, reporting, and handling of missing outcome data in longi-
tudinal studies of TBI, including both clinical trials and observational
studies. Second, to provide an explicit guide for TBI researchers on
how to report and handle their missing outcome data.
Methods
This review was conducted and reported in line with the Co-
chrane guidelines for methodological reviews and the Preferred
Reporting Items for Systematic reviews and Meta-Analyses
(PRISMA) statement for systematic reviews.8,9 The protocol for
this systematic review was registered on PROSPERO and is ac-
cessible online (www.crd.york.ac.uk/PROSPERO/display_record
.php?ID=CRD42017080788).10
Information sources
The following databases were searched up to October 27, 2017:
MEDLINE via OVID, Embase via OVID, Cochrane Central Reg-
ister of Controlled Trials, and Cumulative Index of Nursing and
Allied Health Literature (CINAHL). Search terms relating to
traumatic brain injury were taken from a previously published
living review by the CENTER-TBI group11 and included exploded
MESH terms for ‘‘Brain Injuries’’ or ‘‘Craniocerebral Trauma’’ or
word variations of ‘‘((head* or brain*) adj2 (injur* or trauma*))’’
in the title, abstract, or keywords.12 These were combined with the
following search terms relating to the Glasgow Outcome Scale
(GOS): the exploded MESH term for ‘‘Glasgow Outcome Scale’’;
or word variations of ‘‘(Glasgow Outcome Scale or extended
Glasgow Outcome Scale or GOS or GOSE)’’ or ‘‘((functional or
neur*) adj (status or outcome*))’’ in the title, abstract, or key
words. The search was restricted to studies on human participants.
As missing data guidelines for interventional studies were pub-
lished in 2010,5–7 we only included studies published after 2011 to
allow authors sufficient time to familiarize themselves with the
guidelines and apply them to their study analyses.
Inclusion and exclusion criteria
We included traumatic brain injury studies where GOS13 or
Glasgow Outcome Scale-Extended (GOSE)14 was used as a lon-
gitudinal outcome measure. Although a variety of outcome mea-
sures are employed in TBI research, we were concerned that some
outcome measures could be more prone to non-response than
others. To reduce heterogeneity and allow for a valid comparison of
missing data among the studies, we opted to only select studies with
a common outcome measure. GOS/GOSE was chosen as it is the
most widely used outcome measure and would thus generate the
most representative sample of TBI studies.
GOS was one of the first outcome scores to assess functional
outcome following TBI and remains the most widely cited and
validated score in TBI. The extended version (which includes an
8-point scale rather than a 5-point scale) was also included, with
the two versions showing similar validity.15 GOS is currently re-
commended in head injury by both the National Institute of Neuro-
logical Disorders and Stroke in the United States16 and the Department
of Health in the United Kingdom.17 For the same reasons we only
accepted studies using the adult version of GOS/GOSE. A modified
version of GOSE Peds that takes account of developmental stage
exists and shows a strong association with the standard version.18
Therefore, we accepted studies with a small proportion of children
(<25% of patients under 16 years of age) and excluded studies that
focused on pediatric TBI specifically. Studies that included non-
traumatic etiologies of brain injury were also excluded.
Longitudinal was defined as any study that recruited patients or
started data collection in the acute or subacute phase (within 2
months of injury) and had a single time-point or multiple follow-up
time-points at least 3 months after injury. We selected larger TBI
studies with an arbitrary minimum of 100 patients, in only the
English language as this language was shared by all reviewers.
Both interventional and observational TBI studies were in-
cluded. Interventional studies were defined as involving allocation
of an intervention (investigative or therapeutic) by the researcher to
a study group with a comparison arm. Interventional studies in-
cluded both randomized and non-randomized clinical trials (RCTs
and non-RCTs) differing by the use of randomization in the process
of allocation. In non-randomized clinical trials, treatment or control
allocation occurs through an alternative process from randomiza-
tion. In terms of observational studies, before-and-after studies and
cohort studies were included. Cohorts were defined as studies ob-
serving the effect of a natural exposure on outcome using an un-
exposed group as a control. Both retrospective and prospective
observational studies were included. Before-and-after studies were
defined as studies where interventions arose naturally or uninten-
tionally without formal assignment or allocation with the treatment
effect being compared before and after its implementation.
Case-control studies, case reports, and case series were ex-
cluded, as by definition, these study designs do not have missing
outcome data. Incomplete publications such as posters, abstracts,
and synopses were also excluded as detailed reporting was required
for data extraction.
Study selection and data extraction
Study selection was done using the Covidence systematic review
software.19 Initial screening of abstracts and titles by one reviewer
(SS or SR) excluded irrelevant articles. Eligibility of full texts was
assessed by two reviewers independently (two of SR, SS, and TN).
Data extraction from full texts was performed in duplicate by
two independent reviewers (two of SS, SR, and TN), using a piloted
extraction form. Information was extracted on study design (in-
terventional or observational), cohort characteristics (age and se-
verity of TBI in terms of Glasgow Coma Scale [GCS]) and features
of follow-up. Specifically, we looked at the version of GOS used, its
use as a primary or secondary outcome, and the timing, frequency,
and success of follow-up, defined as the proportion of missing
patients. Timing of follow-up was recorded as occurring at discrete
time-points or within a range of months from initial injury. Pooling
GOS data across a time range is a methodological approach that
itself reduces missing outcome data and was analyzed separately.
When loss to follow-up was not explicitly reported in the text body,
the numbers of patients missing was calculated using values quoted
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in the figures and tables when available. Patients who died prior to
follow-up were not considered to be missing, as their outcome was
known (GOS 1).
We identified and classified five patterns of reporting of missing
outcome data:
1. Sufficient. Authors report complete follow-up achieved on
all patients.
2. Sufficient. Patients lost to follow-up. Authors clearly state
number of patients lost at each time-point.
3. Insufficient. Patients lost to follow-up and total missing re-
ported, but timing unclear.
4. Insufficient. Patients lost to follow-up but number missing
unclear.
5. Insufficient. Authors do not report if patients were missing.
Patterns 1 and 2 are described as sufficient as it is transparent
how many patients were followed up or missing. Studies using
pattern 1 explicitly state they have no missing outcome data. Si-
milarly, pattern 2 studies provide sufficient information to deduce
how many patients were missing at each follow-up point. The re-
maining three patterns reflect insufficient reporting. In pattern 3,
authors follow up patients at more than one time-point. Although
they report how many patients were lost overall, it is unclear at
which time-point patients drop out. In pattern 4, authors state pa-
tients are lost to follow-up but not how many. Studies using pattern
5 offer no comment on the follow-up rate, nor do they provide
information in figures or tables on whether patients were lost.
Therefore, it is unclear whether they indeed managed to follow up
all patients or failed to declare their missing data.
In addition to identifying the reporting pattern, we described
studies in reference to populations they included. Studies that re-
corded the baseline characteristics of all patients initially enrolled,
irrespective of successful follow-up were labeled as having an
‘‘inclusive approach.’’ Alternatively, studies that described only
patients successfully followed up were considered as having an
‘‘exclusive approach.’’
For studies with missing outcome data, we recorded whether
authors explored or stated explicitly the assumed missingness
mechanism. We considered there to be two ways of exploring
missingness. First, authors could compare baseline characteristics
of retained with missing patients, or alternatively, they could
compare the proportion of missing data in interventional or non-
interventional arms in the case of interventional studies or exposed
and unexposed patients in observational studies.
In the event of missing data, we recorded the choice of handling
technique and the use of a sensitivity analyses. Techniques for han-
dling missing data included omission, imputation, and other ad-
vanced statistical analyses. Omission, also known as listwise deletion
involves omission of missing outcome data from the analysis. Im-
putation refers to the substitution of the missing value with an esti-
mate. This can be single or multiple, depending on whether the data
gap is filled by one or several plausible estimates. Advanced statis-
tical techniques use all available information in the data set to predict
outcome. An example includes expectation-maximization algo-
rithms as used in multi-level modeling. We considered the techniques
in reference to the number of time-points, either single or multiple, as
this has implications on the appropriate technique for use.
Once data extraction was complete, two reviewers (SS and SR)
searched for duplicate publications on the same patient cohorts to
ensure a cohort would be included only once. This was done by
comparing numbers, dates, centers, and inclusion criteria for re-
cruitment across all texts. We considered a text to be a duplicate if
another article reported on the identical cohort or reported on a
larger cohort that fully included the smaller cohort. For inclusion in
this review we chose the text that included the larger patient cohort,
or in case of identical size, was published first. If patient cohorts
overlapped only partially, we treated each as a unique cohort.
Disagreements at any stage were resolved through discussion and
consensus with a third reviewer.
Assessment of risk of bias
To assess the quality of research being reviewed, we performed
an assessment of risk of bias. This was done in accordance with the
Cochrane Handbook for Systematic Reviews of Interventions8
using the Cochrane risk of bias tool for clinical trials20 and the
Newcastle-Ottawa Scale21 for cohort studies (see Supplementary
Appendix S1 for details). Briefly, the Cochrane risk of bias tool
looks at seven areas in trial design and implementation with potential
for the introduction of bias. The risk is assessed as high, low, or
unclear. Similarly, the Newcastle-Ottawa Scale assesses the quality
of non-randomized studies including cohorts, in eight domains using
a star system. Each domain could score ‘‘1 star’’ depending on
quality, with the exception of ‘‘comparability of cohorts’’ where 2
stars could be awarded when multiple confounders were controlled
for. Two reviewers assessed risk of bias independently for each study
(two of SS, SR, and TN). Disagreements were resolved through
discussion and consensus with the third reviewer.
Data synthesis
Data were only synthesized for studies that fulfilled eligibility
criteria at full-text review and were included after removing du-
plicate studies on the same patient cohort.
Quantification of missing data was done in two steps, depending
on whether studies used an inclusive or exclusive approach. The
first step was to calculate how many patients were initially enrolled
in each study. The second step involved calculating the number of
patients whose outcome was missing, that is, patients who were
recruited to the study but lacked an outcome.
Authors of studies using the inclusive approach reported the
baseline data on the number of patients enrolled in their study,
irrespective of follow-up. Subsequently, they described the number
of patients at each follow-up time-point. This could be either the
same number in the case of complete follow-up, or a reduced
number due to dropout. The percentage of patients missing was
calculated as per Equation 1:
%Missing¼ Patients missing at followup=Patients enrolledð Þ · 100:
Studies with the exclusive approach, however, provided baseline
data only on the number of patients successfully followed up. If they
also described the number of patients excluded because of lack of
follow-up, this number was added to the number of patients described
and the percentage of missing data calculated as per Equation 2:
%Missing¼ Patients excluded due to lack of followup=ð
ðPatients followedupþ
Patients excluded due to lack of followupÞ·100:
If studies only reported how many patients were successfully
followed up but did not say how many patients were excluded due
to loss to follow-up, then the original number of patients enrolled in
the study could not be calculated.
If studies using the exclusive approach had only contacted pa-
tients at a single time-point, then we knew that all loss to follow-up
had occurred at that time-point. If studies excluded patients due to
loss to follow-up and had tried to contact patients at multiple time-
points, the first of which was hospital discharge, we assumed that
loss to follow-up had occurred at the second time-point.
Statistical analysis
Data were analysed in R version 3.5.0.22 Fisher’s exact test was
used to compare categorical variables and the Mann-Whitney U test
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was used for continuous variables. We compared values between
interventional and observational studies and stated any statistically
significant results. In total, seven variables were compared between
observational and interventional studies, and again between RCTs
and non-RCTs, yielding 14 comparisons. For more robust conclu-
sions, a p-value threshold of 0.005 was chosen.23
Fifteen (7.7%) of the 195 studies did not report on the quantity of
missing outcome. When comparing these with the 180 studies that
did report the proportion of patients missing, no difference was
found in the proportion of interventional versus observational
studies ( p= 1.00), retrospective versus prospective studies
( p = 1.00), studies involving pediatric patients ( p = 0.781), studies
using GOS as a primary versus secondary outcome ( p= 1.00), the
severity profile of patients ( p= 1.00), and the study size as judged
by the number of patients successfully followed up ( p = 0.677).
Formal comparison of these studies with and without reporting,
using Little’s MCAR test24 (from R package ‘‘BaylorEdPsych’’
version 0.5), showed that the MCAR assumption was not rejected
(v2 4.6, p= 0.47). Thus, we simply omitted the 15 studies from
graphical representations relating to the percentage of missing data.
Multi-level modeling of follow-up rates was performed in R
using package ‘‘lme4’’ version 1.1–18-1, with ‘‘Time’’ as a fixed
effect. Studies that pooled GOS across a time range rather than
discrete time-points, and studies that did not report the follow-up
rate were excluded. Thus, a total of 156 studies with 368 follow-up
time-points were included. To account for within-study correlation
of follow-up rates over time, ‘‘Study ID’’ was used as a random
effect to allow for study specific intercepts and slopes.
Results
Search results
The search yielded 269 eligible articles, which reported on 195
unique patient cohorts (Fig. 1). The characteristics of these 195
cohorts, henceforth called ‘‘studies,’’ are summarized in Table 1
(for more detail see Supplementary Appendix S2). Overall the risk
of bias in these studies was judged to be low to moderate (Sup-
plementary Appendix S1).
Twenty-one studies were interventional in design compared with
174 observational studies. Of the 21 interventional studies, there
were 17 parallel RCTs, one cluster RCT, and 3 non-RCTs. Only 1
of the 174 observational studies was a before-and-after study; the
remaining 173 were cohort studies.
Reporting of missing outcome data
Reporting of follow-up was considered sufficient in 64% of
studies. In 14% of studies with sufficient reporting, missing out-
come data were deduced through analysis of figures and tables
rather than explicit description in the text. Although most studies
reported sufficiently, 23% did not report anything on missing out-
comes (Table 2).
Amount of missing outcome data
Follow-up rates varied widely across studies (Fig. 2) and could
only be calculated when both the number enrolled and the number
missing at a specific time-point were known. This occurred in 156
studies. Follow-up rates could not be extracted in 39 studies where
the number of patients initially enrolled could not be calculated
(14 studies), GOS was assessed across a range (24 studies), or
where both situations applied (1 study).
Multi-level modeling predicts a follow-up rate of 91% at 6
months, dropping to 84% at 12 months and 69% at 24 months for
both interventional and observational studies. There was no sig-
nificant difference in the follow-up rate between interventional and
observational studies ( p= 0.528); however, we infrequently ob-
served follow-up beyond 6 months in interventional studies.
In 25 (13%) studies, time to follow-up was presented as a range
and varied considerably within the study. GOS values were pooled
with ranges varying from 3 months to 54 years. The amount of
missing outcome data present in range studies (mean 21%, median
15%) compared with studies with discrete time-points (mean 12%,
median 5%) represented a non-significant trend toward better
follow-up in studies with discrete time-points ( p= 0.039).
Approaches to missing outcome data
In studies with missing outcome data, we observed two broad
approaches to the handling of missing data, referred to as ‘‘inclu-
sive’’ and ‘‘exclusive’’ approaches (Fig. 3).
The inclusive approach was used by two thirds of studies (93 of
139 studies) with missing outcome data (Fig. 3) and the exclusive
approach was used by the remaining third (46 of 139 studies;
Fig. 3). There was a trend of interventional studies preferring the
inclusive approach compared with observational studies (89% vs.
64%, p = 0.035).
Missingness mechanism
An exploration of the missingness mechanisms was attempted
by 69 (50%) of all 139 studies with missing data (Fig. 3). This was
done either by comparing baseline characteristics between retained
and lost patients (28 studies, 20%) and/or by comparing attrition
rates across patient groups (50 studies, 36%). A comparison of
retained and lost patients took the form of a description in text
(3 studies), descriptive statistics (7 studies), and statistical testing
(18 studies). The most common covariates compared included age
(86% of comparisons), TBI severity (75%), sex (71%), mechanism
of injury (39%), and imaging findings (35%). Additional features
compared infrequently included ethnicity, pre-morbid education
and employment status, alcohol abuse, and need for surgery. Of
these studies, 16 (57%) found a difference between the patients lost
and those followed up.
Attrition rates were compared between study arms in 17 of the 18
interventional studies with missing data, with two finding a sub-
stantial difference. Conversely, only 33 of 121 observational
studies with missing outcome data compared attrition rates ac-
cording to the exposure of interest with 10 finding a significant
difference. Thus, observational studies were less likely than trials to
compare attrition rates across groups ( p< 0.0001).
Although 50% of studies appeared to make some attempt to
identify the missingness mechanism, only four explicitly stated
which missingness mechanism they decided to assume for their
analysis: three MAR, one MNAR (Fig. 3).
Handling missing values
Techniques used for handling missing data varied considerably
across studies (Table 3). There was no relationship between the
choice of technique and amount of missing outcome data.
A sensitivity analysis was performed by only 5 of 139 studies
with missing data. All 5 compared single or multiple imputation to
omission.
Discussion
We systematically reviewed the reporting and handling of
missing outcome data in 195 TBI studies with more than 100,000
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FIG. 1. PRISMA flowchart illustrating the search and study inclusion process.
Table 1. Study Characteristics of Included Studies
Study characteristics Interventional Observational Total
Total Studies 21 174 195
Number of patients enrolled 7774 96,914 104,688*
Number of studies by injury severity All severities 5 73 78
Mild 0 8 8
Moderate and severe 16 90 106
Not reported 0 3 3
Studies including pediatric patients 6 (29%) 46 (26%) 52 (27%)
GOS/GOSE is the primary outcome 20 (95%) 143 (82%) 163 (84%)
Follow-up at non-discrete time-points Number (% of studies) 1 (5%) 24 (14%) 25 (13%)
Number of follow-up time-points Mode (range) 1 (1-2) 1 (1-5) 1 (1-5)
Studies with multiple follow-up time-points Number (% of studies) 6 (21%) 43 (25%) 49 (25%)
Follow up duration in months Mean (range) 7.7 (3-26) 12.2 (3-120) 11.6 (3-120)
*Number for the 180 studies for which the number of patients enrolled could be discerned.
GOS/GOSE, Glasgow Outcome Scale/Glasgow Outcome Scale-Extended.
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patients. Attaining complete follow-up for all patients in a study is
extremely challenging and was only achieved for certain in 5% of
studies in our data set. Although we acknowledge this difficulty,
accurate reporting of the number of patients enrolled and subse-
quently followed up is simple and allows readers to meaningfully
interpret outcome data. However, we found over a third of studies did
not provide sufficient information for the reader to discern how many
patients had contributed to the outcome data at defined time-points.
The first step in deciding how to deal with missing values is to
explore why these data are missing, identify the missingness
mechanism, and whether there is a systematic difference between
patients with and without available outcome data. Only half of the
studies attempted this and only four studies documented which
missingness mechanism they assumed. This is surprising consid-
ering that the missingness mechanism determines how missing data
should be handled, and suggests reliance on the default in statistical
programs, which is usually to exclude patients without available data.
These shortcomings are understandable in the observational
studies (the majority of TBI studies), because no guidance exists for
the handling of missing data in this setting. However, guideline
Table 2. Reporting of Follow-Up Utilized Five Patterns
Reporting of follow-up Studies Studies with explicit reporting Patients lost to follow-up
1. Sufficient:
Report achieving complete follow-up
10 (5%) 10 (100%) 0 (0%)
2. Sufficient:
Report number of patients missing at each time-point
115 (59%) 98 (85%) 18,324 (22%)
3. Insufficient:
Report number of patients missing, but timing unclear
9 (5%) 6 (75%) 1559 (20%)
4. Insufficient:
Report patients were missing, but number unclear
15 (8%) 15 (100%) Not reported
5. Insufficient:
Do not report if patients were missing
46 (23%) 0 (0%) Presumed zero
Total 195 (100%) 129 (66%) >19,883 (>19%)
In patterns 1, 2, and 3, authors provide enough information to deduce the total number of patients lost to follow up. In patterns 4 and 5 it is not reported
or presumed to be zero. Therefore, the total number of patients missing in all the studies is unknown and a minimum estimate is given in the bottom right
column. ‘‘Studies with explicit reporting’’ describes studies that state clearly in the text if patients were missing and how many.
FIG. 2. Patient follow-up rate in TBI studies. The left-hand panel displays interventional studies, the right-hand panel observational
studies. Each line represents one study; the circles mark the follow-up time-points with the size reflecting the number of patients initially
enrolled. The dashed line indicates the mean follow-up rate as predicted from the multi-level model. TBI, traumatic brain injury.
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adherence was poor even among interventional studies, which
highlights the need for improved awareness and more explicit
guidance for the handling of missing outcome data within the TBI
community, irrespective of study type. We therefore propose the
following framework (Fig. 4).
When no difference exists between patients with and without
available outcome data (MCAR assumed), exclusion or omission
of lost patients from the analysis will not introduce bias. To de-
cide if data are truly MCAR, it is insufficient to simply compare
baseline means alone. For example, if both extremes of age are
lost to follow-up, the mean age would remain unaffected.
Therefore we recommend comparing distributions of the baseline
characteristics, either by inspection of density plots or using a
formal statistical test, such as Little’s MCAR test.24 Little’s test
will distinguish between MCAR and MAR, but it cannot be used
to exclude or identify MNAR. Whereas omission of patients who
are truly MCAR will not introduce bias, it will nonetheless reduce
power of studies. Therefore, we only recommend this strategy
when the amount of missing data is very small, or alternative
strategies are not possible because auxiliary data are unavailable
(see below).
When missing patients are omitted (the number is small and
MCAR is assumed), baseline data should be presented for patients
successfully followed up, as described by the exclusive approach.
This allows the reader to interpret the study results in the context of
the patients who contributed to outcomes. In this review 76 (55%)
of the 139 studies with missing outcome data presented baseline
data for a larger cohort than the subgroup of patients with available
outcomes (i.e., inclusive approach using ‘‘omission’’). This should
be avoided as it is not transparent and disrupts internal validity,
especially when data are not MCAR.
FIG. 3. Approaches to handling missing data. Nearly half of all studies attempted to explore the ‘‘missingness mechanism.’’ However,
only 4 of all studies explicitly stated the missingness mechanism, with 65 of 69 studies not mentioning a mechanism. *For 15 studies it
is unclear how many patients were enrolled prior to loss to follow-up, so these patients are excluded from the numbers in this flowchart.
Table 3. Frequency of Handling Techniques Used
in the 139 Studies with Missing Outcome Data
Handling
technique
Follow-up
time-points
Single
time-point,
number of
studies
(percent)
Multiple
time-points,
number of
studies
(percent)
Exclusive approach 42 (43%) 4 (10%)
Omission 43 (44%) 33 (79%)
Omission plus single imputation* 4 (4%) 0
Single imputation 3 (3%) 3 (7%)
Multiple imputation 3 (3%) 0
Multi-level model 1 (1%) 2 (5%)
Analysis abandoned 1 (1%) 0
Total 97 (100%) 42 (100%)
*In all cases, omission was combined with ‘‘last observation carried
forward’’ as the technique of single imputation.
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An alternative approach, when data are MAR and sufficient in-
formation is available, is estimation of missing values using mul-
tiple imputation (MI) or advanced statistical techniques such as
multi-level models (MLM).25 These techniques generate unbiased
estimates for missing outcome values and therefore allow for in-
clusion of all patients and preservation of power. In addition, unlike
single imputation where only a single value is estimated, they in-
crease the standard errors to accurately reflect the uncertainty
around estimation. Very few studies in our review used MI or
MLM, which may reflect an unfamiliarity with these techniques.
However, they have now been integrated in many of the main-
stream statistics programs.
Both MI and MLM require some auxiliary information to esti-
mate the missing values, that is, one or more variables that are
correlated with the outcome of interest but are not directly relevant
to the study question. For example, in a study investigating the
effect of age at injury on GOS at 6 months, the use of age to
estimate missing GOS values would be pointless. Ideally, the use of
auxiliary outcome data, for example, GOS values measured at other
time-points or a correlated outcome measure at the same time-point
such as the Quality of Life after Brain Injury (QOLIBRI) Scale,
could be used to estimate and impute the missing value. Ad-
ditionally, covariate data such as GCS or study center can also be
used to provide estimates that even more completely capture any
correlations in the data.
When trying to choose between MI and MLM, one should be
aware that MLM can utilize existing outcome data to predict out-
comes when multiple time-points are used, provided covariate data
are complete. Hence, MI may be needed to impute missing cov-
ariate data prior to multi-level modeling of outcome data itself. In
the event of both missing covariate and outcome data, MI alone
may be easier than multi-level modeling. Both MI and MLM have
been shown to provide similar effect estimates and precision.25
In the event that data are suspected of being MNAR, that is,
when follow-up depends on outcome itself and is not predictable
using other observed information, it should be emphasised that MI
and MLM cannot compensate for bias introduced. Unfortunately,
there is no single test that can be used in isolation to reliably
identify MNAR. We therefore recommend the following red flags
that, in combination, can act as a suite of tools to suspect possible
MNAR:
 The researchers’ suspicion based on their knowledge of the field.
 The amount of auxiliary data available to predict missing
values is low. Note that data that appear to be missing
MNAR can become predictable (and thus MAR) if given
FIG. 4. Decision aid for handling missing outcome data.
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enough auxiliary information. Therefore data from studies
with multiple follow up time-points are unlikely to be
MNAR, if the patient has attended at least one follow-up.
 Reasons recorded during the conduct of the study suggest
MNAR, for example, patients reporting to withdraw from the
studies for reasons related to their outcome status.
 If poor outcome is recorded from a different source than
good outcome, and the source for poor outcome is more
complete. For example, GOS 1 is sourced from the death
registry, whereas GOS 2–5 are recorded in the outpatient
clinic. This could cause MNAR unless circumvented by
using ‘‘data source’’ as a variable in the MI or MLM.
 Attrition rates differ between exposed and unexposed, es-
pecially when patients were randomized to the exposure as in
clinical trials.
When MNAR is suspected, a sensitivity analysis should be
performed, as this can provide insight into the validity of any
conclusions drawn. In the few studies that undertook a sensitivity
analysis, imputation was compared with exclusion of missing
values.26–30 A sensitivity analysis can specifically test any bias that
the researcher is concerned about. For example, if one suspects that
patients with good recovery are less inclined to return for follow-
up, one could specifically impute more favorable outcomes for the
lost patients to assess whether the conclusions still hold.
Our data support previous studies that flagged patient attrition as
a common problem in TBI research.1–3 We have addressed the
issue of handling missing outcome data with the aim of reducing
bias and maintaining study power. Our framework is not designed
to replace diligent follow-up. Ideally, studies should be designed in
such a way as to minimize patient attrition in the first place. Pre-
vious work looking at patient-specific factors predicting dropout
have identified that higher functional status at baseline and lower
socioeconomic background reduce the likelihood of patients at-
tending follow-up, whereas a higher severity of initial injury in-
creases rates of follow-up. Further work should focus on features of
study design that enable researchers to maximize follow-up.
As any analysis, our systematic review has limitations. First, due
to the common language of all the reviewers being English we were
restricted to studies published in this language. However, our data
collection revealed that studies originated from a broad range of
high- and low-income countries. Second, including only large co-
horts (more than 100 TBI patients) may have selected for studies
that were well funded and therefore had better follow-up rates than
less well-funded studies. Therefore, the extent of missing data in
TBI research may be even larger than estimated in this review.
Finally, although we eliminated duplicate cohorts from our studies,
we cannot guarantee exclusion of some patients participating in
more than one cohort.
Conclusion
Missing outcome data in TBI research occurs frequently, is re-
ported inconsistently, and is handled suboptimally. We propose a
framework to handle missing outcome data that is practical and
accessible to the non-statistician.
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